

REVIEW OPEN ACCESS

Highlights Reviews

Regulation and Function of the Atypical I κ Bs—Bcl-3, I κ B_{NS}, and I κ B ζ —in Lymphocytes and Autoimmunity

 Tanja Kübelbeck¹ | Nina Olivera Wichmann² | Timsse Raj³ | Cynthia Raj⁴ | Caspar Ohnmacht² | Nadine Hövelmeyer^{4,5} | Daniela Kramer^{1,5} | Vigo Heissmeyer^{3,6}

¹Department of Dermatology, University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany | ²Center of Allergy and Environment (ZAUM), Technical University and Helmholtz Zentrum München, Munich, Germany | ³Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany | ⁴Institute for Molecular Medicine Mainz, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany | ⁵Research Centre for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany | ⁶Research Unit Molecular Immune Regulation, Molecular Targets and Therapeutics Center, Helmholtz Zentrum München, Munich, Germany

Correspondence: Caspar Ohnmacht (caspar.ohnmacht@helmholtz-munich.de) | Nadine Hövelmeyer (hoelve@uni-mainz.de) | Daniela Kramer (kramerda@uni-mainz.de) | Vigo Heissmeyer (vigo.heissmeyer@med.uni-muenchen.de)

Received: 16 December 2024 | **Revised:** 15 April 2025 | **Accepted:** 16 April 2025

Funding: The research received support from German Research Foundation, TRR355/1 project number 490846870 (TP-A05 to N.H. and C.O., TP-A06 to V.H. and T.P.-A08 to D.K.), CRC1371 project number 395357507 (TP-P07 to C.O.), SFB1292 project number 318346496 (TP-20 to N.H.), FOR2599 project number OH 282/1-2 (TP07 to C.O.), TRR156/3 project number 246807620 (TP-B09 to D.K.) TRR338/1 project number 452881907 (TP-C02 to V.H.), CRC1054/3 project number 210592381 (TP-A03 to V.H.) and grants from the Foundation of Experimental Biomedicine and Boehringer Ingelheim Foundation (D.K.) and the Wilhelm-Sander Foundation (to V.H.).

Keywords: autoimmunity | *Bcl3* | lymphocytes | NF- κ B | *Nfkbid* | *Nfkbiz*

ABSTRACT

Signaling pathways involving NF- κ B transcription factors have essential roles in inflammation, immunity, cell proliferation, differentiation, and survival. Classical I κ B proteins, such as I κ B α and I κ B β , bind to NF- κ B via ankyrin repeats to sequester NF- κ B in the cytoplasm and thus suppress NF- κ B activity. Unlike these constitutively expressed classical I κ Bs, the expression of the atypical I κ Bs Bcl-3, I κ B_{NS}, and I κ B ζ is induced in immune cells after recognition of antigens, pathogen-associated molecular patterns (PAMPs) or cytokines, upon which they localize to the nucleus and form complexes with transcription factors and regulators on the DNA. Atypical, nuclear I κ Bs have been proposed to modulate NF- κ B activity in a context-dependent manner as they can either inhibit or increase gene expression of a subset of NF- κ B target genes. This complexity may be related to the molecular function of atypical I κ Bs, which bind to different transcription factor complexes and form a bridge to different cofactors or epigenetic modifiers. Recent research has identified novel target genes of atypical I κ Bs that include chemokines, cytokines, and master regulators of lymphocyte differentiation, underscoring prominent roles in adaptive immune and autoimmune responses. Here, we summarize our current understanding of atypical I κ Bs in lymphocytes with a focus on their emerging role in autoimmunity.

1 | Introduction

NF- κ B constitutes a family of transcription factors that critically controls immune homeostasis. Thus, mutations and aberrations

within the NF- κ B signaling pathway are associated with various autoinflammatory and autoimmune diseases [1–3]. As NF- κ B controls multiple functions, including survival, proliferation, differentiation, and activation of immune cells, its activity and

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *European Journal of Immunology* published by Wiley-VCH GmbH.




FIGURE 1 | Overview of the regulation and function of the atypical $\text{I}\kappa\text{B}$ proteins, $\text{I}\kappa\text{B}\zeta$ (encoded by *Nfkbiz*), $\text{I}\kappa\text{B}_{\text{NS}}$ (encoded by *Nfkbid*), and Bcl-3 (encoded by *Bcl3*). In resting cells, classical $\text{I}\kappa\text{B}$ s, such as $\text{I}\kappa\text{B}\alpha$ sequester $\text{NF-}\kappa\text{B}$ in the cytoplasm, rendering it inactive. Upon stimulation, $\text{NF-}\kappa\text{B}$ is translocated into the nucleus. Subsequently, together with multiple other transcription factors such as STATs or CEBP, $\text{NF-}\kappa\text{B}$ transcriptionally induces the expression of atypical $\text{I}\kappa\text{B}$ s. Moreover, Regnase-1 and 3 as well as Roquin-1 and 2 regulate the mRNA stability or expression of *Nfkbid* and *Nfkbiz*, thereby modifying the overall expression of $\text{I}\kappa\text{B}\zeta$ and $\text{I}\kappa\text{B}_{\text{NS}}$. Upon protein expression of the atypical $\text{I}\kappa\text{B}$ s, all three members associated with different transcription factor complexes, thereby recruiting other (epi)-genetic co-factors, changing chromatin accessibility, and ultimately gene expression of a subset of $\text{NF-}\kappa\text{B}$ target genes. Please note that miRNA-mediated regulation has been proposed for all three atypical $\text{I}\kappa\text{B}$ s, however, it is not displayed in this figure, since a physiologic relevance for lymphocyte function has not been demonstrated, yet.

effects on target gene expression have to be tightly controlled. $\text{I}\kappa\text{B}$ proteins comprise a key family of $\text{NF-}\kappa\text{B}$ -related co-factors that not only regulate the overall activity of $\text{NF-}\kappa\text{B}$ but also the expression of subgroups of $\text{NF-}\kappa\text{B}$ target genes. This class of co-factors can be roughly distinguished into classical $\text{I}\kappa\text{B}$ s such as $\text{I}\kappa\text{B}\alpha$ and $\text{I}\kappa\text{B}\beta$, the precursor p105 and p100 that are processed to p50 and p52, respectively, and the atypical $\text{I}\kappa\text{B}$ s, such as Bcl-3 , $\text{I}\kappa\text{B}\zeta$, and $\text{I}\kappa\text{B}_{\text{NS}}$. Whereas classical $\text{I}\kappa\text{B}$ s and the precursors p105 and p100 retain $\text{NF-}\kappa\text{B}$ in the cytoplasm in the absence of $\text{NF-}\kappa\text{B}$ signaling, the protein family of atypical $\text{I}\kappa\text{B}$ s, Bcl-3 (encoded by *Bcl3*), $\text{I}\kappa\text{B}\zeta$ (encoded by *Nfkbiz*), and $\text{I}\kappa\text{B}_{\text{NS}}$ (encoded by *Nfkbid*), are inducibly expressed upon activation of $\text{NF-}\kappa\text{B}$ (Figure 1). Subsequently, these atypical $\text{I}\kappa\text{B}$ s interact with $\text{NF-}\kappa\text{B}$, but also with other transcription factors on the chromatin to promote or suppress the transcriptional induction of a subset of $\text{NF-}\kappa\text{B}$ target genes (Figure 1). Initial research on the atypical $\text{I}\kappa\text{B}$ proteins has compared them to classical $\text{I}\kappa\text{B}$ s and uncovered a preference for binding to p50 or p52 homodimers over p65/p50 heterodimers [4–11]. While a cocrystal structure for the classical $\text{I}\kappa\text{B}$, $\text{I}\kappa\text{B}\alpha$, in complex with $\text{NF-}\kappa\text{B}$

p50/p65 has been solved [12], the interaction of atypical $\text{I}\kappa\text{B}$ s remains undefined at the structural level. Various investigations on the physiologic importance, interaction partners, and downstream function of atypical $\text{I}\kappa\text{B}$ s have been performed, but their exact role and mechanism of action are still poorly defined.

Given their flexible protein interactions, target gene regulation, and dynamic expression patterns, a direct comparison between studies is difficult. Thus, genetic models have been instrumental in understanding atypical $\text{I}\kappa\text{B}$ functions and underscore the prominent role of these molecules in lymphocytes and immune responses. Mouse knockout models of all three atypical $\text{I}\kappa\text{B}$ s (*Bcl3*, *Nfkbid*, and *Nfkbiz*) showed unperturbed development, but immune functions and cytokine production were altered already at homeostasis, during immune responses or in disease models [10, 13–18]. The current challenge is to understand when and how the expression of Bcl-3 , $\text{I}\kappa\text{B}_{\text{NS}}$, and $\text{I}\kappa\text{B}\zeta$ is induced, what functions these proteins have in different cell types, which genes they regulate, and how they impact the gene regulatory networks to

control the differentiation of immune cells and affect the immune system or immune responses.

As a large part of our knowledge has been obtained in the mouse system, we will in this review, unless specified otherwise, refer to the mouse genes, the mRNAs encoded in the mouse, and functions of the proteins in the cells of the mouse immune system. A major focus of this review is placed on the role of atypical I κ B in lymphocytes, trying to understand how these factors impact the development of immune-related diseases and autoimmunity.

2 | Molecular Features of Atypical I κ B Proteins

An overview of the genomic structure and regulation of all three atypical I κ B proteins is shown in Figure 2. Of note, although multiple isoforms have already been described for the atypical I κ Bs, isoform-specific functions have only rarely been investigated so far.

I κ B ζ , encoded by *Nfkbiz*, was originally identified as a protein called MAIL, short for molecule possessing ankyrin repeats induced by lipopolysaccharide. It was also termed INAP, which stands for interleukin (IL)-1 inducible nuclear ankyrin-repeat protein [19, 20]. The N-terminus of I κ B ζ differs from the other I κ B proteins [11], providing additional interaction sites with other transcription factors such as POU and STAT proteins. It also contains a transactivation domain (TAD), although the functionality of this domain remains under debate [21, 22]. Earlier publications suggested selective I κ B ζ complex formation with p50 and p52 homodimers, which themselves lack a TAD, consequently leading to an I κ B ζ -dependent activation of NF- κ B target genes [22–24]. Other publications showed I κ B ζ binding to p65:p50 heterodimers and p50 homodimers, and involvement in the inhibition of DNA-binding of these dimers [21, 25, 26]. I κ B ζ is expressed in nonhematopoietic cells such as keratinocytes, fibroblasts, and chondrocytes [19, 27–30], as well as in innate and adaptive immune cells [10, 31–36].

I κ B_{NS}, encoded by *Nfkbid*, is the smallest member of the atypical I κ B protein family [6]. It contains six ankyrin repeats which interact with NF- κ B [37]. I κ B_{NS} was originally identified in a study on negative selection (NS) in the thymus and has been suggested to interact with all members of the NF- κ B family in vitro [6]. Later studies determined p50 as the main interaction partner in macrophages [7] as well as p50:c-Rel heterodimers in CD4⁺ T cells or Treg cells [9]. Promoter studies investigating regulators of I κ B_{NS} expression are so far lacking, although NF- κ B is likely to be involved. I κ B_{NS} has been described to be expressed in adaptive and innate immune cells and lung epithelial cells [7, 9, 13, 18, 38–43].

Bcl-3 (B cell leukemia 3 protein) is a proto-oncogene that was originally identified by its translocation into the immunoglobulin alpha-locus in some patients with chronic lymphocytic leukemia. It contains amino-terminal and carboxy-terminal TADs [44, 45]. The seven ankyrin repeats of Bcl-3 interact with NF- κ B p50 or p52 homodimers and early studies suggested that Bcl-3 represses the binding of these homodimers to DNA [4, 8, 46, 47]. Of note, many cell types express Bcl-3 at a steady state, and its expression can

be further induced by TLR activation in myeloid cells and other NF- κ B-inducing agents. This process may partially depend on p50 expression [48].

3 | Regulation

In most of the studied cell types, such as keratinocytes or T-cells, *Nfkbiz* transcription, and I κ B ζ protein expression are induced in response to a variety of different NF- κ B- and STAT-activating stimuli (Table 1), which is followed by rapid proteasomal degradation of the I κ B ζ protein [49–51]. The E3 ubiquitin ligase PDLIM2 may mediate I κ B ζ proteasomal degradation, at least in myeloid cells [51]. Moreover, multiple threonine phosphorylation sites have been identified in I κ B ζ , which can switch I κ B ζ from a gene activator to a gene repressor by promoting the recruitment of HDAC1 to target gene promoters [21] (Figure 2C). The *Nfkbiz* mRNA is also posttranscriptionally regulated by the endoribonuclease activities of Regnase-1 and Regnase-3 which bind to a defined *cis*-element composed of several stem-loop structures in the 3'-UTR of *Nfkbiz* and induce mRNA decay but also translational inhibition [52–56] (Figure 2B). The inhibitory effect of Regnase-1 can also be counteracted by Arid5a, which, during IL-17 stimulation, seems to interfere with Regnase-1 activity, stabilizes *Nfkbiz* mRNA, and promotes I κ B ζ protein expression [57]. Regnase-1 is a target of MALT1 proteolytic cleavage [58], and *Nfkbiz*/I κ B ζ expression is strongly triggered by MALT1 activation in T cells [59]. Moreover, treatment of macrophages and keratinocytes with itaconate suppressed LPS-induced I κ B ζ expression, possibly through ATF3-dependent repression [60]. MicroRNAs also regulate *NFKBIZ* mRNA stability. In detail, miR-376b and miR-124a can inhibit *NFKBIZ* expression, while miR-376b and *Nfkbiz* have an impact on liver regeneration, tubular damage, and intrarenal inflammation in acute kidney injury [61–63].

I κ B_{NS} protein expression and *Nfkbid* transcription are induced by several stimuli including antigen receptors, TLRs, or cytokine receptors (Table 1), but the *Nfkbid* mRNA is also placed under profound posttranscriptional control. The 3'-UTR of the *Nfkbid* mRNA harbors several stem-loop structures that form a *cis*-element [64], very similar to the one defined in *Nfkbiz* [52] (Figure 2B). Both *cis*-elements contain one or two constitutive decay elements (CDEs), which are known to be recognized by the Roquin family of RNA-binding proteins, namely Roquin-1 and its redundantly functioning paralog Roquin-2 [52, 64–68]. *Nfkbid*/I κ B_{NS} mRNA and protein expression are regulated by Roquin-1 via induced mRNA decay that involves deadenylation and decapping as well as inhibition of translation [64]. Very similar to I κ B ζ , I κ B_{NS} is strongly derepressed upon activation of the MALT1 protease, which is explained by Roquin-1 and Roquin-2 being MALT1 substrates [59, 69]. In fact, I κ B_{NS} induction upon TCR signaling closely follows the proteolytic cleavage of Roquin proteins and is prevented by MALT1 inhibition or mutations of the MALT1-specific cleavage sites in Roquin-1 [59, 70]. *NFKBID* is also regulated by microRNA. It has been shown that miR-492 binds *NFKBID* and leads to the downregulation of *NFKBID* mRNA levels in the context of Zika virus replication [71].




FIGURE 2 | Gene structure, transcriptional and posttranscriptional regulation, and posttranslational modifications of Bcl-3, I κ B Ns , and I κ B ζ . (A) Gene structure. I κ B ζ is encoded by two different variants of *Nfkbiz*, resulting from alternative splicing, and thus generates two different proteins consisting of 728 and 629 amino acids. Of note, both variants contain unique promoter regions which can be occupied by canonical NF- κ B, STAT1-3 or CEBP [126–128]. Besides 7 ankyrin repeats, it contains a nuclear localization signal (NLS), a potential TAD, and an OCA domain [19, 129]. Direct interaction and mapping of the interaction sites have already been identified for POU transcription factors [129], STAT3 [130], and NF- κ B p50, p52, and p65 [10, 131]. The smallest member of atypical I κ Bs is I κ B Ns , encoded by *Nfkbid*, which exists in three different isoforms through splicing events at the 5'-UTR, leading to the generation of a 327 amino acid long protein. Our schematic omits a putative isoform of I κ B Ns (470 aa) since this isoform has not been experimentally verified. It consists of 6 ankyrin repeats which mediate the interaction with NF- κ B p50, p52, and c-Rel. Of note, no reporter promoter studies of *Nfkbid* have been published so far. Bcl-3 (encoded by *Bcl3*) consists of 448 amino acids, and contains two transactivation domains (TAD) and 7 ankyrin (ANK) repeats [4, 132]. Moreover, several promoter studies revealed that Bcl-3 expression is induced by binding of either canonical or noncanonical NF- κ B signaling [133], as well as STAT1 [134] and STAT3 [135]. Direct interactions of Bcl-3 with AP1 [76] and p50/p52 have been reported [136–138]. (B) Posttranscriptional regulation. *Nfkbiz* and *Nfkbid*, but not *Bcl3*, are posttranscriptionally regulated by Regnase-1 and 3 and Roiquin-1 and 2. Regnase and Roiquin proteins can bind at the 3'-UTR, thus inducing mRNA decay and inhibiting translation of I κ B ζ and I κ B Ns at steady state [52, 59, 64]. (C) Posttranslational modifications. Apart from transcription and posttranscriptional regulation, posttranslational modifications of Bcl-3 and I κ B ζ have been described, that modify their activity, binding to interaction partners, and overall function. Of note, no posttranslational modifications have been described for I κ B Ns so far.

TABLE 1 | Expression stimuli, target genes, and interaction partners of atypical I κ B ζ .

	I κ B ζ	I κ B N_S	Bcl-3
Stimulus and receptor leading to expression	B-cell: BCR [35]	B-cell: Tlr1/2 (Pam3CSK4) [108] Tlr4 (LPS) [108] Tlr6/2 (FSC-1) [108] Tlr7 (Imiquimod) [108] Tlr9 (ODN1826) [108] BCR [100, 103]	
	T-cell: Il6r (IL-6) [36] Tgfr (TGF- β) [36]	T-cell: TCR (IL-2, CD3, and CD28) [9, 59, 70]	
Target genes	B-cell: <i>Il10</i> [35], <i>Ctla4</i> [35], <i>Cd86</i> [35], <i>Tnfa</i> [35, 99]	B-cell: <i>Pax5</i> [106], <i>Blimp1</i> [106, 107]	
	T-cell: <i>Il17a</i> [36], <i>Il17f</i> [36], <i>Il21</i> [36], <i>Il22</i> [36], <i>Il23r</i> [36] Treg: <i>Foxp3</i> [82]	T-cell: <i>Bcl6</i> [85], <i>Il2</i> [18, 83], <i>Il10</i> [83], <i>Ccl3</i> [83], <i>Csf2</i> [18, 83], <i>Il17f</i> [84], <i>Ccr6</i> [84] Treg: <i>Foxp3</i> [9]	T-cell: <i>Gata3</i> [93] <i>Rorc</i> [94] <i>Bim</i> [90] Treg: <i>Ctla4</i> [92], <i>Foxp3</i> [92], <i>Il2r</i> [92], <i>Il10</i> [92]
Interaction partner	p50, p65 [26]—in macrophages Akirin2 [139]—in macrophages POU transcription factors [129]—HEK293T C/EBP β , STAT3, STAT1 [127]—in HaCaT API, KLF4 [126]—in HaCaT PDLIM2 [51]—in macrophages ROR γ t and ROR α [36]—in CD4 $^+$ -T-cells (some experiments Th17 condition) <i>Foxp3</i> [82]—in EL-4/LAF	p50 [7]—in macrophages p65, Rel, Relb [6]—in thymic extracts from N15 TCRtg mice cRel, p50 [9]—in CD4 $^+$ CD25 $^-$ Tcon	p50 [92]—in Tregs p52 [140]—in macrophages HDAC1 [48]—in macrophages

Bcl-3 protein levels are regulated via posttranslational modifications, especially phosphorylation and ubiquitination (Figure 2C). Under resting conditions, Bcl-3 degradation and oncogenicity are regulated by protein kinase GSK3 β -mediated phosphorylation [72, 73]. However, the proteasomal degradation in the cytoplasm was shown to be independent of GSK3 [74]. The ability of Bcl-3 to affect gene transcription depends on its phosphorylation by AKT, ERK2, and IKK1/2, which enable the regulation of NF- κ B p52 and p50 homodimer transcriptional activity [73]. Translocation from the cytoplasm to the nucleus requires K-63-linked polyubiquitination [73]. The deubiquitinating enzyme CYLD has been shown to control Bcl-3 localization in keratinocytes by removing polyubiquitin chains upon UV irradiation. This prevents nuclear accumulation and consequently Bcl-3-mediated regulation of gene transcription [75]. Bcl-3 can suppress transcription by recruiting transcriptional co-repressors. This was specifically demonstrated by the recruitment of HDAC1 and the subsequent suppression of TNF production in macrophages upon LPS stimulation [48]. The recruitment of the co-repressor CtBP by Bcl-3 was associated with increased Bcl-3 stability and enhancement of its suppressive capacity [74]. Bcl-3 can also activate gene transcription by forming a ternary complex with p50 homodimers, inducing transcription through its TADs [4]. The interaction of Bcl-3 with proteins such as histone acetyltransferases (e.g., p300 and Tip60) suggests, among others, a putative role of Bcl-3 in chromatin remodeling [76, 77]. Lastly, Bcl-3 expression may also be repressed by the microRNAs miR-125b and miR-19a [78, 79] but functional investigations for the relevance of these observations in noncancerous cells are still lacking.

4 | Function in T Cells

I κ B ζ is highly expressed in Th17 cells compared with other T helper cell subsets. Combined IL-6 and TGF- β stimulation triggers its induction in Th17 cells, which depends on STAT3 [36]. While CD4 $^+$ T cells isolated from global *Nfkbiz* knockout mice exhibit normal Th17 differentiation, they completely lose IL-17A expression in a ROR γ t and ROR α -dependent manner (Table 1). Consequently, no experimental autoimmune encephalomyelitis (EAE) was induced when CD4 $^+$ T cells from global *Nfkbiz* knockout mice were transferred into *Rag2* knockout mice [36]. Furthermore, MaruYama et al. [80] explored the role of I κ B ζ in T cells using Lck-Cre *Nfkbiz* knockout mice. These mice developed lymphadenopathy, splenomegaly, and leukocyte infiltration in various tissues and organs between 6-18 months of age. In younger mice, deletion of *Nfkbiz* resulted in increased numbers of Treg cells and effector/memory CD4 $^+$ T cells as well as increased serum levels of IFN- γ and IL-2. These effects may be partly due to the use of the Lck-Cre, as a report implied adverse and off-target effects in the Lck-Cre line, and wild-type mice without Lck-Cre were used as controls [81]. Oppositely, a Treg-specific knockout of *Nfkbiz* did not show significant differences in the numbers of effector T cells, thymic-derived Treg cells, or expression levels of key cytokines [80]. In contrast, Treg cells from Lck-Cre *Nfkbiz* knockout mice exhibited reduced immunoregulatory function in a T-cell transfer colitis model. Further studies suggested that I κ B ζ can bind to the *Foxp3* promoter in the presence of TGF- β in Treg cells and can inhibit *Foxp3* expression by interfering with p65 transactivation [82], thereby possibly interfering with Treg differentiation or function (Table 1).

$I\kappa B_{NS}$ is expressed in both effector and regulatory T cells [9, 18, 83]. Although global *Nfkbid* knockout mice did not show changes in immune cell populations within the thymus or peripheral lymphoid organs, conditional inactivation reveals a proliferation defect of $I\kappa B_{NS}$ -deficient $CD4^+$ and $CD8^+$ T cells in vitro, which can be rescued by exogenous IL-2 and IL-7 supplementation [13, 18]. $I\kappa B_{NS}$ -deficient T cells expressed lower levels of IL-2 and IFN- γ [18]. They also showed a specific impairment in the induction of ROR γ t in response to TGF β and IL-6 and were less capable of differentiating into the Th17 subset, exhibiting reduced expression of IL-17A and Th17-related genes as compared with wild-type counterparts [84] (Table 1). *Citrobacter rodentium* infections revealed that the absence of $I\kappa B_{NS}$ significantly reduced the infiltration of IL-17A $^+$ T-cells into the gut lamina propria [83]. $I\kappa B_{NS}$ does not directly regulate *Il17a* transcription, but instead interacts with the *Il10* gene locus, as shown by chromatin immunoprecipitation (ChIP) [83, 84] (Table 1). In *Listeria monocytogenes* (*L.m.*) infections $I\kappa B_{NS}$ was required for the induction of *L.m.*-Ova-specific Th1 cells and effector cytokine production. Although $I\kappa B_{NS}$ expression was necessary during the early stages of Th1 priming, it did not affect T-bet expression [39]. Additional roles for $I\kappa B_{NS}$ in promoting Tfh cell differentiation were described and direct regulation of the Tfh signature genes, *Bcl6* and *Il21*, was confirmed in ChIP experiments [85]. $I\kappa B_{NS}$ also plays a critical role in thymic Treg development. In ChIP experiments $I\kappa B_{NS}$ bound to the conserved noncoding region 3 (CNS3) in the *Foxp3* promoter via p50 and c-Rel, and $I\kappa B_{NS}$ was required for the induction of *Foxp3* but dispensable for CD25 expression [86] (Table 1). *Nfkbid*-deficient Treg cells accumulated in the GITR $^+$ CD25 $^+$ *Foxp3* $^-$ precursor stage, failing to progress into mature thymic Treg cells, which caused a 50% reduction in mature peripheral Treg cells [9]. Functionally, *Nfkbid*-deficient Treg cells were unable to protect from T-cell transfer-induced colitis [9]. In mature Treg cells, *Nfkbid* is suppressed by *Foxp3* and is not required for the maintenance or suppressive function of Treg cells [9, 87].

Bcl-3 was shown early on to be highly expressed in tolerogenic T cells and to directly control the formation of NF- κ B dimers and IL-2 production [88]. Bcl-3 was proposed to slow down T cell activation early after stimulation by a T cell-intrinsic mechanism [89]. Like its function in other cell types, Bcl-3 controls survival and apoptosis following activation of T cells: overexpression of Bcl-3 increases survival, while Bcl-3 deficiency accelerates cell death. The anti-apoptotic activity of Bcl-3 is partially based on the inhibition of the proapoptotic molecule Bim, since Bim was overactivated in Bcl-3-deficient T cells, and forced Bcl-3 expression kept T cells alive but failed to promote the survival of Bim-deficient T cells [90] (Table 1). In line with these results, mixed bone marrow chimeras showed that Bcl-3-deficient thymocytes were outcompeted by wild-type cells; however, this effect was completely reversed in the intestinal lamina propria, presumably due to high amounts of Th17 and Treg cells at this site, and the strong effects of Bcl-3 in restraining these cells [91]. Importantly, $CD4^+$ T cells overexpressing Bcl-3 fail to induce colitis in a T cell transfer-induced colitis experiment, presumably due to impaired proliferation of these cells in vivo, which is a prerequisite for inducing colitis in this model [92]. Bcl-3 has unique roles in different T helper cell subsets. For example, in vitro differentiation of Th2, but not Th1 cells, is impaired in Bcl-3-deficient T cells [93], as Bcl-3 together with p50 transactivates the *GATA3*

promoter [93] (Table 1). In Th1 cells, Bcl-3 expression suppresses trans-differentiation toward less pathogenic Th17-like cells [94]. Mechanistically, Bcl-3 prevents the binding of c-Rel and p50 at the *RORC* locus and Bcl-3-deficient Th1 cells already show higher *Rorc* expression [94] (Table 1). Similarly, Bcl-3-deficient animals harbor elevated frequencies of (nonpathogenic) Th17 cells in the lamina propria of the small intestine, while overexpression of Bcl-3 in T cells results in impaired Th17 differentiation in vitro and reduced frequencies of Th17 cells in the lamina propria of the small intestine [91, 95]. Pathogenicity of Th17 cells, indicated by co-expression of IFN- γ and GM-CSF, may be regulated by Bcl-3 at the metabolic level because enhanced glycolysis and lower respiration are observed in Bcl-3-deficient Th17 cells [96]. Bcl-3 directly interacts with Raptor, one of the mTORC1 components, to control cell metabolism of Th17 cells [96]. Noteworthy, Bcl-3-deficient animals harbor elevated numbers of Treg cells in various compartments whereas T-cell-specific overexpression of Bcl-3 results in impaired Treg cell differentiation and function [91, 92]. This is not only true for thymic-derived Treg cells, but also for microbiome-induced Treg cells co-expressing ROR γ t [91, 97]. Additionally, there is also some evidence that Bcl-3 affects the differentiation of $CD8^+$ T cells, thereby limiting terminal effector cell differentiation and promoting memory cell formation [98].

5 | Function in B cells

$I\kappa B\zeta$ expression is induced in B cells by activation of the BCR and/or by co-stimulation with TLR9/TLR7 [35, 99]. $I\kappa B\zeta$ -deficient mice showed impaired proliferation of B cells after TLR9 stimulation compared with wild-type mice, but not after BCR stimulation. There were no differences in the number of mature B cells, follicular B cells, and the expression of surface markers such as IgM, Fc γ RIIB, and TLR9 in *Nfkbiz*-deficient mice. In contrast, a slightly reduced number of transitional B cells and a slightly increased number of marginal zone B cells were present in these mice. Likewise, no difference in NF- κ B activation of $I\kappa B\zeta$ -deficient B cells could be detected after TLR9 stimulation [35].

However, individual genes show differences in expression in $I\kappa B\zeta$ -deficient B cells, including *Il10*, *Ctla4*, *Tnf*, and *Cd86* expression, although some of these effects were stimulus-dependent (Table 1) [35].

$I\kappa B_{NS}$ expression is rapidly induced in B cells at the mRNA and protein level in response to LPS, anti-CD40, and anti-IgM stimulation [38, 100]. $I\kappa B_{NS}$ -deficient mice, or mice that harbor a premature stop codon in the *Nfkbid* gene, also known as *bumble* mice, completely lack B1 cells, show a delayed IgG response, and fail to differentiate toward plasma cells [38, 101-103]. Additionally, *bumble* mice have severely reduced marginal zone (MZ) B cells and reduced IgM levels in the circulation. The MZ B cell compartment was restored to normal levels in aged *bumble* mice; however, these cells were not functional [104]. Interestingly, mice carrying a heterozygous *bumble* mutation also showed reduced IgM production despite having normal B cell development, which suggests a requirement for full $I\kappa B_{NS}$ expression from two *Nfkbid* alleles [105]. Furthermore, $I\kappa B_{NS}$ was shown to be required for the generation of plasma blasts and plasma cells in response to LPS stimulation. In *bumble* B

cells, expression of *Pax5* and *Blimp1* which regulate plasma cell differentiation is increased (Table 1). This is accompanied by an excessive metabolic activity observed in *bumble* B cells that leads to impaired T-cell-independent antibody responses [106, 107]. Similar to T cells, $\text{I}\kappa\text{B}_{\text{NS}}$ was required for IL-10 production by B cells following TLR stimulation, at least during the initial phases of induction, with IL-10 expression normalizing over time [108].

Bcl-3-deficient mice show a requirement for Bcl-3 in the germinal center reaction and immunization-induced antibody responses [15, 109]. The diminished humoral immune responses may explain why Bcl-3-deficient mice show impaired clearance of *Listeria monocytogenes*, *Streptococcus pneumoniae*, and *Toxoplasma* infections [14, 15, 109]. In contrast, the $\text{E}\mu\text{-Bcl3}$ transgenic mice, in which Bcl-3 is overexpressed in B and T cells, display splenomegaly and an accumulation of mature B-cells in secondary lymphoid organs [110]. Transgenic mice that overexpress or lack Bcl-3 specifically in B cells show that Bcl-3 is a pivotal regulator of B cell fate determination. Loss of Bcl-3 leads to an increase in marginal zone B cells and a reduction in follicular B cells, whereas overexpression of Bcl-3 causes the opposite phenotype [111, 112]. Furthermore, Bcl-3 promotes the survival and proliferation of B cell receptor-stimulated B cells while impairing responses to LPS [112]. Bcl-3 modulates the growth capacity of B cells, where its overexpression is linked to reduced proliferation upon activation, likely due to decreased cell death rather than increased growth [111, 112]. Taken together, Bcl-3 possesses antiapoptotic properties that are critical for safeguarding B cells from programmed cell death.

6 | Atypical $\text{I}\kappa\text{B}$ s in Autoimmunity and Autoinflammation

Given their importance in B and T cells, it is plausible that atypical $\text{I}\kappa\text{B}$ s play pivotal roles in spontaneous autoimmunity or experimental models of brain or gut autoimmunity and autoinflammation.

6.1 | Spontaneous Disease

Global *Nfkbiz*-deficient mice show 90% lethality during embryogenesis. 4–8-week-old mice develop lesions resembling atopic dermatitis that affect the face and neck and are characterized by strong infiltration of leukocytes [16, 113]. This phenotype has been related to Sjögren's syndrome and is associated with enhanced apoptosis due to $\text{I}\kappa\text{B}\zeta$ deficiency in epithelial cells of the lacrimal gland as well as the formation of Sjögren's syndrome-associated autoantibodies in the serum of *Nfkbiz* knockout mice [28]. Interestingly, the salivary glands are also affected, since female *Nfkbiz*-deficient mice show a reduced salivary flow rate, which was associated with dysbiotic oral microbiota and focal lymphocytic sialadenitis [114].

Global *Nfkbid*-deficient mice or mice deficient in both $\text{I}\kappa\text{B}_{\text{NS}}$ and c-Rel do not show any signs of autoimmunity or severe abnormalities in the development of the immune system, despite having a reduced Treg cell compartment [18]. The lack of autoimmunity has been attributed to the impaired activation of conventional T-cells, which may balance the loss of Treg cells [115]. Interestingly,

NOD mice express a hypermorphic *Nfkbid* allele which leads to a reduction in negative selection of diabetogenic CD8^+ cells and may therefore contribute to autoimmune diabetes [116].

Global *Bcl3* knockout mice also do not show signs of autoimmunity, whereas the combined absence of *Bcl3* and *Nfkb2* results in the loss of central tolerance and autoimmunity [117]. This phenotype manifests despite the presence of elevated numbers of Treg cells in the context of Bcl-3 deficiency. Although *Bcl3*-deficient mice do not suffer from spontaneous autoimmunity, they are more susceptible to streptozotocin-induced type 1 diabetes [118]. Also, in the context of systemic lupus erythematosus (SLE)-like disease, Bcl-3 was shown to play a protective role, since *Bcl3*-deficient mice carrying the *lpr* mutation developed a more severe SLE-like inflammatory phenotype than control *lpr* mice [119]. In line with this observation, forced overexpression of Bcl-3 in T cells impaired Treg cell development and function, resulting in a spontaneous colitis phenotype [92]. Even though not related to autoimmunity, *Bcl3* deficiency also resulted in resistance to skeletal muscle atrophy, a phenomenon that is phenotypically mimicked in p105/p50 (*Nfkb1*) knockout mice [120].

6.2 | Experimental Autoimmune Encephalomyelitis

Resistance to EAE has been reported for *Nfkbid* and *Nfkbiz* knockout mice; in both cases, the phenotype is T-cell-intrinsic and can be explained by reduced Th17 differentiation [36, 84]. Surprisingly, both Bcl-3 deficiency in T cells and conditional overexpression of Bcl-3 in CD4^+ T cells protect mice from the development of EAE [94, 95]. This protection is associated with a strong reduction of immune cells infiltrating the central nervous system of both models. Resistance to EAE can be explained by the trans-differentiation of Th1 cells to nonpathogenic Th17 cells in Bcl-3-deficient mice, whereas T cells overexpressing Bcl-3 fail to differentiate into pathogenic Th17 cells [94, 95].

6.3 | Gut-Related Inflammation

Global *Nfkbiz* knockout mice exhibit greater weight loss after dextran sulfate sodium (DSS) treatment and develop more severe colitis as determined by histopathological analysis [121]. However, mice with epithelial-specific deletion of *Nfkbiz* (*Vill-Cre*) show similar levels of DSS-induced inflammation as control mice, which suggests that the observed phenotype is driven by immune rather than epithelial cells [122]. Consistently, it has been shown that in patients with ulcerative colitis, the inflamed gut is remodeled by pervasive clones. Many of these clones are positively selected by the acquisition of mutations, often affecting the *NFKBIZ* gene. Consequently, these mutations are involved in the downregulation of IL-17 signaling, and proinflammatory signaling [122–124]. In contrast, global *Bcl3*-knockout mice are less susceptible than wild-type mice to DSS-induced colitis. The absence of Bcl-3 was associated in one study with enhanced epithelial cell turnover and regeneration, despite similar levels of inflammation compared with wild-type counterparts [125], whereas in another study, protection from DSS-induced colitis was associated with elevated frequencies of $\text{ROR}\gamma\text{t}$ -expressing Treg cells [97]. Mice with a T-cell-specific overexpression of Bcl-3

develop more severe colitis that can be attributed to defective Treg cell development and function [92].

In a transfer-induced colitis model, *Rag1*^{-/-} mice receiving *Nfk-bid* knockout T cells developed a more severe form of colitis, characterized by an increase in IFN- γ ⁺ T cells and a complete loss of IL-17A-producing cells [83]. In contrast, *Rag1*^{-/-} mice that received Bcl-3-deficient T cells were protected from transfer-induced colitis. Upon transfer of naïve T cells into *Rag1*^{-/-} recipients, Bcl-3 deficiency resulted in a preferential differentiation to nonpathogenic Th17 cells and a reduced differentiation toward pathogenic Th1 cells and/or further trans-differentiation of Th1 cells into nonpathogenic Th17 cells [94]. Additionally, Bcl-3-deficient T cells may preferentially differentiate toward ROR γ ⁺ Treg cells, with increased frequencies of both thymic and microbiome-induced ROR γ ⁺ Treg cells potentially contributing to protection against colitis [91, 97].

In summary, all these observations suggest an important contribution of all three atypical I κ Bs, Bcl-3, I κ B_{NS}, and I κ B ζ , in the differentiation and functionality of T and B cells. The impact of these molecules is controlled and finetuned at the transcriptional, posttranscriptional, and posttranslational levels all together enabling the time- and context-dependent regulation of adaptive immune cells. Thus, we propose that atypical I κ Bs serve to enhance flexibility for the use of NF- κ B-dependent gene regulation and harmonize this functionality with other pathways such as control of chromatin accessibility or cell metabolism with—if disturbed—important consequences for autoimmune disorders and intestinal inflammation.

7 | Conclusion and Outlook

The investigation of atypical I κ Bs began with gene identification, followed by characterization of the gene products, examination of their regulation, and generation of mouse models with global or conditional knockouts or overexpression. The various approaches have generated numerous indications that implicate these factors in the control of T and B cell activation, differentiation, and survival and the development of autoimmune diseases. However, despite the use of similar approaches and models, in many cases, differing experimental setups preclude direct comparisons. Consequently, fundamental questions remain unanswered. For example, is the involvement of I κ B_{NS}, and I κ B ζ in the same cell types and phenotypes and in the same molecular processes explained by redundant or cooperative functions? Which target genes are bound by individual atypical I κ Bs in a specific cell type? Which NF- κ B homo- or heterodimers are bound by these atypical I κ Bs in cells? Through which of the proposed mechanisms do they regulate the expression of specific target genes?

In future research, it will be crucial to reassess specific functions in parallel using conditional inactivation of floxed alleles with the same Cre lines and to generate double knockout models that can answer questions about redundancy. The studies of atypical I κ Bs in T cells have focused more on T helper cells, therefore additional studies will now be required to describe their role in cytotoxic T cells during infections to provide information for a more balanced view. We propose that biochemical and bioinformatic approaches to determine genome-wide interactions will be essential for

advancing our understanding. Specifically, developing comprehensive and comparative genome-wide binding maps for Bcl-3, I κ B_{NS}, and I κ B ζ in the same cell type, using Cut&Run or Cut&Tag technologies would be an invaluable resource to uncover the function of atypical I κ Bs, especially in lymphocytes and in the setting of autoimmunity and autoinflammatory diseases.

Acknowledgments

The authors acknowledge funding support from the German Research Foundation, TRR355/1 project number 490846870 (TP-A05 to NH and CO, TP-A06 to VH, and TP-A08 to DK), CRC1371 project number 395357507 (TP-P07 to CO), SFB1292 project number 318346496 (TP-20 to NH), FOR2599 project number OH 282/1-2 (TP07 to CO), TRR156/3 project number 246807620 (TP-B09 to DK) TRR338/1 project number 452881907 (TP-C02 to VH), CRC1054/3 project number 210592381 (TP-A03 to VH) and grants from the Foundation of Experimental Biomedicine and Boehringer Ingelheim Foundation (DK) and the Wilhelm-Sander Foundation (to VH).

Open access funding enabled and organized by Projekt DEAL.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Peer Review

The peer review history for this article is available at <https://publons.com/publon/10.1002/eji.202451273>.

References

1. Q. Guo, Y. Jin, X. Chen, et al., “NF- κ B in Biology and Targeted Therapy: New Insights and Translational Implications,” *Signal Transduct Target Ther* 9, no. 1 (2024): 53, [10.1038/s41392-024-01757-9](https://doi.org/10.1038/s41392-024-01757-9).
2. T. Liu, L. Zhang, D. Joo, and S. C. Sun, “NF-kappaB Signaling in Inflammation,” *Signal Transduct Target Ther* 2 (2017): 17023, [10.1038/sigtrans.2017.23](https://doi.org/10.1038/sigtrans.2017.23).
3. Q. Zhang, M. J. Lenardo, and D. Baltimore, “30 Years of NF-kappaB: A Blossoming of Relevance to Human Pathobiology,” *Cell* 168, no. 1-2 (2017): 37–57, [10.1016/j.cell.2016.12.012](https://doi.org/10.1016/j.cell.2016.12.012).
4. V. Bours, G. Franzoso, V. Azarenko, et al., “The Oncoprotein Bcl-3 Directly Transactivates Through Kappa B Motifs via Association With DNA-binding p50B Homodimers,” *Cell* 72, no. 5 (1993): 729–739, [10.1016/0092-8674\(93\)90401-b](https://doi.org/10.1016/0092-8674(93)90401-b).
5. J. H. Caamano, P. Perez, S. A. Lira, and R. Bravo, “Constitutive Expression of Bcl-3 in Thymocytes Increases the DNA Binding of NF-kappaB1 (p50) Homodimers in Vivo,” *Molecular and Cellular Biology* 16, no. 4 (1996): 1342–1348, [10.1128/MCB.16.4.1342](https://doi.org/10.1128/MCB.16.4.1342).
6. E. Fiorini, I. Schmitz, W. E. Marissen, et al., “Peptide-induced Negative Selection of Thymocytes Activates Transcription of an NF-kappa B Inhibitor,” *Molecular Cell* 9, no. 3 (2002): 637–648, [10.1016/s1097-2765\(02\)00469-0](https://doi.org/10.1016/s1097-2765(02)00469-0).
7. T. Hirotani, P. Y. Lee, H. Kuwata, et al., “The Nuclear IkappaB Protein IkappaBNS Selectively Inhibits Lipopolysaccharide-induced IL-6 Production in Macrophages of the Colonic Lamina Propria,” *Journal of Immunology* 174, no. 6 (2005): 3650–3657, [10.4049/jimmunol.174.6.3650](https://doi.org/10.4049/jimmunol.174.6.3650).
8. G. P. Nolan, T. Fujita, K. Bhatia, et al., “The Bcl-3 Proto-Oncogene Encodes a Nuclear I κ B-Like Molecule That Preferentially Interacts With

- NF- κ B p50 and p52 in a Phosphorylation-Dependent Manner,” *Molecular and Cellular Biology* 13, no. 6 (1993): 3557–3566, [10.1128/mcb.13.6.3557-](https://doi.org/10.1128/mcb.13.6.3557-).
9. M. Schuster, R. Glauben, C. Plaza-Sirvent, et al., “I κ B(NS) Protein Mediates Regulatory T Cell Development via Induction of the Foxp3 Transcription Factor,” *Immunity* 37, no. 6 (2012): 998–1008, [10.1016/j.immuni.2012.08.023](https://doi.org/10.1016/j.immuni.2012.08.023).
 10. M. Yamamoto, S. Yamazaki, S. Uematsu, et al., “Regulation of Toll/IL-1-receptor-mediated Gene Expression by the Inducible Nuclear Protein IkappaBzeta,” *Nature* 430, no. 6996 (2004): 218–222, [10.1038/nature02738](https://doi.org/10.1038/nature02738).
 11. S. Yamazaki, T. Muta, and K. Takeshige, “A Novel IkappaB Protein, IkappaB-zeta, Induced by Proinflammatory Stimuli, Negatively Regulates Nuclear Factor-kappaB in the Nuclei,” *Journal of Biological Chemistry* 276, no. 29 (2001): 27657–27662, [10.1074/jbc.M103426200](https://doi.org/10.1074/jbc.M103426200).
 12. T. Huxford, D. B. Huang, S. Malek, and G. Ghosh, “The Crystal Structure of the IkappaBalpha/NF-kappaB Complex Reveals Mechanisms of NF-kappaB Inactivation,” *Cell* 95, no. 6 (1998): 759–770, [10.1016/s0092-8674\(00\)81699-2](https://doi.org/10.1016/s0092-8674(00)81699-2).
 13. H. Kuwata, M. Matsumoto, K. Atarashi, et al., “IkappaBNS Inhibits Induction of a Subset of Toll-Like Receptor-dependent Genes and Limits Inflammation,” *Immunity* 24, no. 1 (2006): 41–51, [10.1016/j.immuni.2005.11.004](https://doi.org/10.1016/j.immuni.2005.11.004).
 14. M. Riemann, R. Endres, S. Liptay, K. Pfeffer, and R. M. Schmid, “The IkappaB Protein Bcl-3 Negatively Regulates Transcription of the IL-10 Gene in Macrophages,” *Journal of Immunology* 175, no. 6 (2005): 3560–3568, [10.4049/jimmunol.175.6.3560](https://doi.org/10.4049/jimmunol.175.6.3560).
 15. E. M. Schwarz, P. Krimpenfort, A. Berns, and I. M. Verma, “Immunological Defects in Mice With a Targeted Disruption in Bcl-3,” *Genes & development* 11, no. 2 (1997): 187–197, [10.1101/gad.11.2.187](https://doi.org/10.1101/gad.11.2.187).
 16. T. Shiina, A. Konno, T. Oonuma, et al., “Targeted Disruption of MAIL, a Nuclear IkappaB Protein, Leads to Severe Atopic Dermatitis-Like Disease,” *Journal of Biological Chemistry* 279, no. 53 (2004): 55493–55498, [10.1074/jbc.M409770200](https://doi.org/10.1074/jbc.M409770200).
 17. I. Tassi, E. Claudio, H. Wang, et al., “The NF- κ B Regulator Bcl-3 Governs Dendritic Cell Antigen Presentation Functions in Adaptive Immunity,” *Journal of Immunology* 193, no. 9 (2014): 4303–4311, [10.4049/jimmunol.1401505](https://doi.org/10.4049/jimmunol.1401505).
 18. M. Touma, V. Antonini, M. Kumar, et al., “Functional Role for I Kappa BNS in T Cell Cytokine Regulation as Revealed by Targeted Gene Disruption,” *Journal of Immunology* 179, no. 3 (2007): 1681–1692, [10.4049/jimmunol.179.3.1681](https://doi.org/10.4049/jimmunol.179.3.1681).
 19. T. Shiina, M. Morimatsu, H. Kitamura, et al., “Genomic Organization, Chromosomal Localization, and Promoter Analysis of the Mouse Mail Gene,” *Immunogenetics* 53, no. 8 (2001): 649–655, [10.1007/s00251-001-0376-x](https://doi.org/10.1007/s00251-001-0376-x).
 20. P. Gautam, S. Maenner, F. Cailotto, et al., “Emerging Role of I κ B ζ in Inflammation: Emphasis on Psoriasis,” *Clinical and translational medicine* 12, no. 10 (2022): e1032, [10.1002/ctm2.1032](https://doi.org/10.1002/ctm2.1032).
 21. P. Gronдона, P. Bucher, A. Schmitt, et al., “Threonine Phosphorylation of I κ B ζ Mediates Inhibition of Selective Proinflammatory Target Genes,” *Journal of Investigative Dermatology* 140, no. 9 (2020): 1805–1814, [10.1016/j.jid.2019.12.036](https://doi.org/10.1016/j.jid.2019.12.036).
 22. M. Motoyama, S. Yamazaki, A. Eto-Kimura, K. Takeshige, and T. Muta, “Positive and Negative Regulation of Nuclear Factor-kappaB-mediated Transcription by IkappaB-zeta, an Inducible Nuclear Protein,” *Journal of Biological Chemistry* 280, no. 9 (2005): 7444–7451, [10.1074/jbc.M412738200](https://doi.org/10.1074/jbc.M412738200).
 23. D. V. Trinh, N. Zhu, G. Farhang, B. J. Kim, and T. Huxford, “The Nuclear I kappaB Protein I kappaB Zeta Specifically Binds NF-kappaB p50 Homodimers and Forms a Ternary Complex on kappaB DNA,” *Journal of Molecular Biology* 379, no. 1 (2008): 122–135, [10.1016/j.jmb.2008.03.060](https://doi.org/10.1016/j.jmb.2008.03.060).
 24. S. Matsuo, S. Yamazaki, K. Takeshige, and T. Muta, “Crucial Roles of Binding Sites for NF-kappaB and C/EBPs in IkappaB-zeta-Mediated Transcriptional Activation,” *Biochemical Journal* 405, no. 3 (2007): 605–615, [10.1042/bj20061797](https://doi.org/10.1042/bj20061797).
 25. Y. Feng, Z. Chen, Y. Xu, et al., “The central Inflammatory Regulator I κ B ζ : Induction, Regulation and Physiological Functions,” *Frontiers in immunology* 14 (2023): 1188253, [10.3389/fimmu.2023.1188253](https://doi.org/10.3389/fimmu.2023.1188253).
 26. A. E. Daly, G. Yeh, S. Soltero, and S. T. Smale, “Selective Regulation of a Defined Subset of Inflammatory and Immunoregulatory Genes by an NF- κ B p50-I κ B ζ Pathway,” *Genes & development* 38, no. 11-12 (2024): 536–553, [10.1101/gad.351630.124](https://doi.org/10.1101/gad.351630.124).
 27. S. Yamazaki, T. Muta, S. Matsuo, and K. Takeshige, “Stimulus-specific Induction of a Novel Nuclear Factor-kappaB Regulator, IkappaB-zeta, via Toll/Interleukin-1 Receptor Is Mediated by mRNA Stabilization,” *Journal of Biological Chemistry* 280, no. 2 (2005): 1678–1687, [10.1074/jbc.M409983200](https://doi.org/10.1074/jbc.M409983200).
 28. A. Okuma, K. Hoshino, T. Ohba, et al., “Enhanced Apoptosis by Disruption of the STAT3-I κ B- ζ Signaling Pathway in Epithelial Cells Induces Sjögren’s Syndrome-Like Autoimmune Disease,” *Immunity* 38, no. 3 (2013): 450–460, [10.1016/j.immuni.2012.11.016](https://doi.org/10.1016/j.immuni.2012.11.016).
 29. C. Y. Kao, C. Kim, F. Huang, and R. Wu, “Requirements for Two Proximal NF-kappaB Binding Sites and IkappaB-zeta in IL-17A-Induced Human Beta-Defensin 2 Expression by Conducting Airway Epithelium,” *Journal of Biological Chemistry* 283, no. 22 (2008): 15309–15318, [10.1074/jbc.M708289200](https://doi.org/10.1074/jbc.M708289200).
 30. M. Arra, G. Swarnkar, Y. Alippe, G. Mbalaviele, and Y. Abu-Amer, “I κ B- ζ Signaling Promotes Chondrocyte Inflammatory Phenotype, Senescence, and Erosive Joint Pathology,” *Bone Res* 10, no. 1 (2022): 12, [10.1038/s41413-021-00183-9](https://doi.org/10.1038/s41413-021-00183-9).
 31. S. Seshadri, Y. Kannan, S. Mitra, J. Parker-Barnes, and M. D. Wewers, “MAIL Regulates Human Monocyte IL-6 Production,” *Journal of Immunology* 183, no. 8 (2009): 5358–5368, [10.4049/jimmunol.0802736](https://doi.org/10.4049/jimmunol.0802736).
 32. M. Cardone, A. K. Dzutsev, H. Li, et al., “Interleukin-1 and Interferon- γ Orchestrate β -Glucan-Activated Human Dendritic Cell Programming via I κ B- ζ Modulation,” *PLoS ONE* 9, no. 12 (2014): e114516, [10.1371/journal.pone.0114516](https://doi.org/10.1371/journal.pone.0114516).
 33. Y. Kannan, J. Yu, R. M. Raices, et al., “I κ B ζ Augments IL-12- and IL-18-Mediated IFN- γ Production in Human NK Cells,” *Blood* 117, no. 10 (2011): 2855–2863, [10.1182/blood-2010-07-294702](https://doi.org/10.1182/blood-2010-07-294702).
 34. H. Ohto-Ozaki, M. Hayakawa, N. Kamoshita, T. Maruyama, S. I. Tominaga, and T. Ohmori, “Induction of I κ B ζ Augments Cytokine and Chemokine Production by IL-33 in Mast Cells,” *Journal of Immunology* 204, no. 8 (2020): 2033–2042, [10.4049/jimmunol.1900315](https://doi.org/10.4049/jimmunol.1900315).
 35. F. Hanihara, Y. Takahashi, A. Okuma, T. Ohba, and T. Muta, “Transcriptional and Post-Transcriptional Regulation of I κ B- ζ Upon Engagement of the BCR,” *TLRs and Fc γ R Int Immunol* 25, no. 9 (2013): 531–544, [10.1093/intimm/dxt017](https://doi.org/10.1093/intimm/dxt017).
 36. K. Okamoto, Y. Iwai, M. Oh-Hora, et al., “IkappaBzeta Regulates T(H)17 Development by Cooperating With ROR Nuclear Receptors,” *Nature* 464, no. 7293 (2010): 1381–1385, [10.1038/nature08922](https://doi.org/10.1038/nature08922).
 37. B. Manavalan, S. Basith, Y. M. Choi, G. Lee, and S. Choi, “Structure-Function Relationship of Cytoplasmic and Nuclear I κ B Proteins: An in Silico Analysis,” *PLoS ONE* 5, no. 12 (2010): e15782, [10.1371/journal.pone.0015782](https://doi.org/10.1371/journal.pone.0015782).
 38. M. Touma, D. B. Keskin, F. Shiroki, et al., “Impaired B Cell Development and Function in the Absence of IkappaBNS,” *Journal of Immunology* 187, no. 8 (2011): 3942–3952, [10.4049/jimmunol.1002109](https://doi.org/10.4049/jimmunol.1002109).
 39. S. Frenzel, A. Jeron, A. Pausder, et al., “I κ B(NS)-deficiency Protects Mice From Fatal Listeria Monocytogenes Infection by Blunting Pro-Inflammatory Signature in Ly6C(high) Monocytes and Preventing Exaggerated Innate Immune Responses,” *Frontiers in immunology* 13 (2022): 1028789, [10.3389/fimmu.2022.1028789](https://doi.org/10.3389/fimmu.2022.1028789).
 40. T. Niida, K. Isoda, M. Kitagaki, et al., “I κ BNS Regulates Interleukin-6 Production and Inhibits Neointimal Formation After Vascular Injury

- in Mice," *Cardiovascular Research* 93, no. 2 (2011): 371–379, [10.1093/cvr/cvr323](https://doi.org/10.1093/cvr/cvr323).
41. M. Yokota, T. Tamachi, Y. Yokoyama, et al., "I κ BNS Induces Muc5ac Expression in Epithelial Cells and Causes Airway Hyper-responsiveness in Murine Asthma Models," *Allergy* 72, no. 7 (2017): 1043–1053, [10.1111/all.13079](https://doi.org/10.1111/all.13079).
42. S. Fujita, K. Seino, K. Sato, et al., "Regulatory Dendritic Cells Act as Regulators of Acute Lethal Systemic Inflammatory Response," *Blood* 107, no. 9 (2006): 3656–3664, [10.1182/blood-2005-10-4190](https://doi.org/10.1182/blood-2005-10-4190).
43. M. Yamamoto and K. Takeda, "Role of Nuclear I κ B Proteins in the Regulation of Host Immune Responses," *Journal of Infection and Chemotherapy* 14, no. 4 (2008): 265–269, [10.1007/s10156-008-0619-y](https://doi.org/10.1007/s10156-008-0619-y).
44. M. Schuster, M. Annemann, C. Plaza-Sirvent, and I. Schmitz, "Atypical I κ B Proteins—Nuclear Modulators of NF- κ B Signaling," *Cell Communication and Signaling* 11, no. 1 (2013): 23, [10.1186/1478-811x-11-23](https://doi.org/10.1186/1478-811x-11-23).
45. H. Ohno, G. Takimoto, and T. W. McKeithan, "The Candidate Proto-Oncogene Bcl-3 Is Related to Genes Implicated in Cell Lineage Determination and Cell Cycle Control," *Cell* 60, no. 6 (1990): 991–997, [10.1016/0092-8674\(90\)90347-h](https://doi.org/10.1016/0092-8674(90)90347-h).
46. T. Fujita, G. P. Nolan, H. C. Liou, M. L. Scott, and D. Baltimore, "The Candidate Proto-Oncogene Bcl-3 Encodes a Transcriptional Coactivator That Activates Through NF-kappa B p50 Homodimers," *Genes & development* 7, no. 7b (1993): 1354–1363, [10.1101/gad.7.7b.1354](https://doi.org/10.1101/gad.7.7b.1354).
47. F. G. Wulczyn, M. Naumann, and C. Scheidereit, "Candidate Proto-Oncogene Bcl-3 Encodes a Subunit-Specific Inhibitor of Transcription Factor NF-kappa B," *Nature* 358, no. 6387 (1992): 597–599, [10.1038/358597a0](https://doi.org/10.1038/358597a0).
48. J. Wessells, M. Baer, H. A. Young, et al., "BCL-3 and NF-kappaB p50 Attenuate Lipopolysaccharide-Induced Inflammatory Responses in Macrophages," *Journal of Biological Chemistry* 279, no. 48 (2004): 49995–50003, [10.1074/jbc.M404246200](https://doi.org/10.1074/jbc.M404246200).
49. K. Sundaram, S. Mitra, M. A. Gavrilin, and M. D. Wewers, "House Dust Mite Allergens and the Induction of Monocyte Interleukin 1 β Production That Triggers an I κ B ζ -Dependent Granulocyte Macrophage Colony-Stimulating Factor Release From Human Lung Epithelial Cells," *American Journal of Respiratory Cell and Molecular Biology* 53, no. 3 (2015): 400–411, [10.1165/rcmb.2014-0370OC](https://doi.org/10.1165/rcmb.2014-0370OC).
50. T. Bertelsen, C. Ljungberg, T. Litman, et al., "I κ B ζ Is a Key Player in the Antipsoriatic Effects of Secukinumab," *Journal of Allergy and Clinical Immunology* 145, no. 1 (2020): 379–390, [10.1016/j.jaci.2019.09.029](https://doi.org/10.1016/j.jaci.2019.09.029).
51. A. Kimura, M. Kitajima, K. Nishida, et al., "NQO1 Inhibits the TLR-dependent Production of Selective Cytokines by Promoting I κ B- ζ Degradation," *Journal of Experimental Medicine* 215, no. 8 (2018): 2197–2209, [10.1084/jem.20172024](https://doi.org/10.1084/jem.20172024).
52. G. Behrens, R. Winzen, N. Rehage, et al., "A Translational Silencing Function of MCP1/Regnase-1 Specified by the Target Site Context," *Nucleic Acids Res.* 46, no. 8 (2018): 4256–4270, [10.1093/nar/gky106](https://doi.org/10.1093/nar/gky106).
53. S. Dhamija, R. Winzen, A. Doerrie, et al., "Interleukin-17 (IL-17) and IL-1 Activate Translation of Overlapping Sets of mRNAs, Including That of the Negative Regulator of Inflammation, MCP1," *Journal of Biological Chemistry* 288, no. 26 (2013): 19250–19259, [10.1074/jbc.M113.452649](https://doi.org/10.1074/jbc.M113.452649).
54. A. V. Garg, N. Amaty, K. Chen, et al., "MCP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation," *Immunity* 43, no. 3 (2015): 475–487, [10.1016/j.immuni.2015.07.021](https://doi.org/10.1016/j.immuni.2015.07.021).
55. B. Liu, J. Huang, A. Ashraf, et al., "The RNase MCP1 Promotes Skin Inflammation by Orchestrating Myeloid Cytokine Response," *Nature Communications* 12, no. 1 (2021): 4105, [10.1038/s41467-021-24352-w](https://doi.org/10.1038/s41467-021-24352-w).
56. T. Uehata, S. Yamada, D. Ori, et al., "Regulation of Lymphoid-Myeloid Lineage Bias Through Regnase-1/3-Mediated Control of Nfkbiz," *Blood* 143, no. 3 (2024): 243–257, [10.1182/blood.2023020903](https://doi.org/10.1182/blood.2023020903).
57. N. Amaty, E. E. Childs, J. A. Cruz, et al., "IL-17 Integrates Multiple Self-reinforcing, Feed-Forward Mechanisms Through the RNA Binding Protein Arid5a," *Science signaling* 11, no. 551 (2018), [10.1126/scisignal.aat4617](https://doi.org/10.1126/scisignal.aat4617).
58. T. Uehata, H. Iwasaki, A. Vandenbon, et al., "Malt1-Induced Cleavage of Regnase-1 in CD4(+) Helper T Cells Regulates Immune Activation," *Cell* 153, no. 5 (2013): 1036–1049, [10.1016/j.cell.2013.04.034](https://doi.org/10.1016/j.cell.2013.04.034).
59. K. M. Jeltsch, D. Hu, S. Brenner, et al., "Cleavage of Roquin and Regnase-1 by the Paracaspase MALT1 Releases Their Cooperatively Repressed Targets to Promote T(H)17 Differentiation," *Nature Immunology* 15, no. 11 (2014): 1079–1089, [10.1038/ni.3008](https://doi.org/10.1038/ni.3008).
60. M. Bambouskova, L. Gorvel, V. Lampropoulou, et al., "Electrophilic Properties of Itaconate and Derivatives Regulate the I κ Bzeta-ATF3 Inflammatory Axis," *Nature* 556, no. 7702 (2018): 501–504, [10.1038/s41586-018-0052-z](https://doi.org/10.1038/s41586-018-0052-z).
61. C. Lindenblatt, K. Schulze-Osthoff, and G. Totzke, "I κ Bzeta Expression Is Regulated by miR-124a," *Cell Cycle* 8, no. 13 (2009): 2019–2023, [10.4161/cc.8.13.8816](https://doi.org/10.4161/cc.8.13.8816).
62. Z. Liu, C. Tang, L. He, et al., "The Negative Feedback Loop of NF-kappaB/miR-376b/NFKBIZ in Septic Acute Kidney Injury," *JCI Insight* 5, no. 24 (2020), [10.1172/jci.insight.142272](https://doi.org/10.1172/jci.insight.142272).
63. S. Lu, H. Jiao, J. Xu, Y. Zheng, Y. Sun, and H. Chen, "Downregulation of IL6 Targeted MiR-376b May Contribute to a Positive IL6 Feedback Loop during Early Liver Regeneration in Mice," *Cellular Physiology and Biochemistry* 37, no. 1 (2015): 233–242, [10.1159/000430348](https://doi.org/10.1159/000430348).
64. K. Essig, N. Kronbeck, J. C. Guimaraes, et al., "Roquin Targets mRNAs in a 3'-UTR-Specific Manner by Different Modes of Regulation," *Nature Communications* 9, no. 1 (2018): 3810, [10.1038/s41467-018-06184-3](https://doi.org/10.1038/s41467-018-06184-3).
65. K. Leppek, J. Schott, S. Reitter, F. Poetz, M. C. Hammond, and G. Stoecklin, "Roquin Promotes Constitutive mRNA Decay via a Conserved Class of Stem-loop Recognition Motifs," *Cell* 153, no. 4 (2013): 869–881, [10.1016/j.cell.2013.04.016](https://doi.org/10.1016/j.cell.2013.04.016).
66. A. Schlundt, G. A. Heinz, R. Janowski, et al., "Structural Basis for RNA Recognition in Roquin-mediated Post-Transcriptional Gene Regulation," *Nature structural & molecular biology* 21, no. 8 (2014): 671–678, [10.1038/nsmb.2855](https://doi.org/10.1038/nsmb.2855).
67. G. Stoecklin, M. Lu, B. Rattenbacher, and C. Moroni, "A Constitutive Decay Element Promotes Tumor Necrosis Factor Alpha mRNA Degradation via an AU-rich Element-Independent Pathway," *Molecular and Cellular Biology* 23, no. 10 (2003): 3506–3515, [10.1128/mcb.23.10.3506](https://doi.org/10.1128/mcb.23.10.3506).
68. K. U. Vogel, S. L. Edelmann, K. M. Jeltsch, et al., "Roquin Paralogs 1 and 2 Redundantly Repress the Icos and Ox40 Costimulator mRNAs and Control Follicular Helper T Cell Differentiation," *Immunity* 38, no. 4 (2013): 655–668, [10.1016/j.immuni.2012.12.004](https://doi.org/10.1016/j.immuni.2012.12.004).
69. A. Gewies, O. Gorka, H. Bergmann, et al., "Uncoupling Malt1 Threshold Function From Paracaspase Activity Results in Destructive Autoimmune Inflammation," *Cell reports* 9, no. 4 (2014): 1292–1305, [10.1016/j.celrep.2014.10.044](https://doi.org/10.1016/j.celrep.2014.10.044).
70. H. Schmidt, T. Raj, T. J. O'Neill, et al., "Unrestrained Cleavage of Roquin-1 by MALT1 Induces Spontaneous T Cell Activation and the Development of Autoimmunity," *PNAS* 120, no. 48 (2023): e2309205120, [10.1073/pnas.2309205120](https://doi.org/10.1073/pnas.2309205120).
71. L. Kang, H. Xie, H. Ye, et al., "Hsa_circ_0007321 Regulates Zika Virus Replication Through miR-492/NFKBID/NF-kappaB Signaling Pathway," *Journal of Virology* 97, no. 12 (2023): e0123223, [10.1128/jvi.01232-23](https://doi.org/10.1128/jvi.01232-23).
72. P. Viatour, E. Dejardin, M. Warnier, et al., "GSK3-Mediated BCL-3 Phosphorylation Modulates Its Degradation and Its Oncogenicity," *Molecular Cell* 16, no. 1 (2004): 35–45, [10.1016/j.molcel.2004.09.004](https://doi.org/10.1016/j.molcel.2004.09.004).
73. V. Y. Wang, Y. Li, D. Kim, et al., "Bcl3 Phosphorylation by Akt, Erk2, and IKK Is Required for Its Transcriptional Activity," *Molecular Cell* 67, no. 3 (2017): 484–497.e5, [10.1016/j.molcel.2017.06.011](https://doi.org/10.1016/j.molcel.2017.06.011).
74. A. Keutgens, K. Shostak, P. Close, et al., "The Repressing Function of the Oncoprotein BCL-3 Requires CtBP, While Its Polyubiquitination

- and Degradation Involve the E3 Ligase TBLR1," *Molecular and Cellular Biology* 30, no. 16 (2010): 4006–4021, [10.1128/mcb.01600-09](https://doi.org/10.1128/mcb.01600-09).
75. R. Massoumi, K. Chmielarska, K. Hennecke, A. Pfeifer, and R. Fässler, "Cyd1 Inhibits Tumor Cell Proliferation by Blocking Bcl-3-Dependent NF-kappaB Signaling," *Cell* 125, no. 4 (2006): 665–677, [10.1016/j.cell.2006.03.041](https://doi.org/10.1016/j.cell.2006.03.041).
76. R. Dechend, F. Hirano, K. Lehmann, et al., "The Bcl-3 Oncoprotein Acts as a Bridging Factor Between NF-kappaB/Rel and Nuclear co-regulators," *Oncogene* 18, no. 22 (1999): 3316–3323, [10.1038/sj.onc.1202717](https://doi.org/10.1038/sj.onc.1202717).
77. N. Watanabe, T. Iwamura, T. Shinoda, and T. Fujita, "Regulation of NFKB1 Proteins by the Candidate Oncoprotein BCL-3: Generation of NF-kappaB Homodimers From the Cytoplasmic Pool of p50-p105 and Nuclear Translocation," *Embo Journal* 16, no. 12 (1997): 3609–3620, [10.1093/emboj/16.12.3609](https://doi.org/10.1093/emboj/16.12.3609).
78. Y. Guan, H. Yao, Z. Zheng, G. Qiu, and K. Sun, "MiR-125b Targets BCL3 and Suppresses Ovarian Cancer Proliferation," *International Journal of Cancer* 128, no. 10 (2011): 2274–2283, [10.1002/ijc.25575](https://doi.org/10.1002/ijc.25575).
79. E. Mogilyansky and I. Rigoutsos, "The miR-17/92 Cluster: A Comprehensive Update on Its Genomics, Genetics, Functions and Increasingly Important and Numerous Roles in Health and Disease," *Cell Death and Differentiation* 20, no. 12 (2013): 1603–1614, [10.1038/cdd.2013.125](https://doi.org/10.1038/cdd.2013.125).
80. T. MaruYama, S. Kobayashi, K. Ogasawara, A. Yoshimura, W. Chen, and T. Muta, "Control of IFN-gamma Production and Regulatory Function by the Inducible Nuclear Protein IxB-epsilon in T Cells," *J Leukoc Biol* 98, no. 3 (2015): 385–393, [10.1189/jlb.2A0814-384R](https://doi.org/10.1189/jlb.2A0814-384R).
81. B. Carow, Y. Gao, J. Coquet, and M. Reilly, "Rottenberg ME. Ick-Driven Cre Expression Alters T Cell Development in the Thymus and the Frequencies and Functions of Peripheral T Cell Subsets," *Journal of Immunology* 197, no. 6 (2016): 2261–2268, [10.4049/jimmunol.1600827](https://doi.org/10.4049/jimmunol.1600827).
82. T. MaruYama, "TGF-beta-induced IxB-epsilon Controls Foxp3 Gene Expression," *Biochemical and Biophysical Research Communications* 464, no. 2 (2015): 586–589, [10.1016/j.bbrc.2015.07.013](https://doi.org/10.1016/j.bbrc.2015.07.013).
83. M. Annemann, Z. Wang, C. Plaza-Sirvent, et al., "IxBNS Regulates Murine Th17 Differentiation During Gut Inflammation and Infection," *Journal of Immunology* 194, no. 6 (2015): 2888–2898, [10.4049/jimmunol.1401964](https://doi.org/10.4049/jimmunol.1401964).
84. S. Kobayashi, A. Hara, T. Isagawa, I. Manabe, K. Takeda, and T. MaruYama, "The Nuclear IxB family Protein IxBNS Influences the Susceptibility to Experimental Autoimmune Encephalomyelitis in a Murine Model," *PLoS ONE* 9, no. 10 (2014): e110838, [10.1371/journal.pone.0110838](https://doi.org/10.1371/journal.pone.0110838).
85. J. Hosokawa, K. Suzuki, K. Meguro, et al., "IxBNS Enhances Follicular Helper T-cell Differentiation and Function Downstream of ASCL2," *Journal of Allergy and Clinical Immunology* 140, no. 1 (2017): 288–291, [10.1016/j.jaci.2016.10.047](https://doi.org/10.1016/j.jaci.2016.10.047).
86. M. Schuster, C. Plaza-Sirvent, A. Visekruna, J. Huehn, and I. Schmitz, "Generation of Foxp3(+)CD25(-) Regulatory T-Cell Precursors Requires c-Rel and IxB(NS)," *Frontiers in immunology* 10 (2019): 1583, [10.3389/fimmu.2019.01583](https://doi.org/10.3389/fimmu.2019.01583).
87. A. Marson, K. Kretschmer, G. M. Frampton, et al., "Foxp3 occupancy and Regulation of Key Target Genes During T-cell Stimulation," *Nature* 445, no. 7130 (2007): 931–935, [10.1038/nature05478](https://doi.org/10.1038/nature05478).
88. S. Grundström, P. Anderson, P. Scheipers, and A. Sundstedt, "Bcl-3 and NFkappaB p50-p50 Homodimers Act as Transcriptional Repressors in Tolerant CD4+ T Cells," *Journal of Biological Chemistry* 279, no. 9 (2004): 8460–8468, [10.1074/jbc.M312398200](https://doi.org/10.1074/jbc.M312398200).
89. M. F. J. Bassetti, J. White, J. W. Kappler, and P. Marrack, "Transgenic Bcl-3 Slows T Cell Proliferation," *International Immunology* 21, no. 4 (2009): 339–348, [10.1093/intimm/dxp002](https://doi.org/10.1093/intimm/dxp002).
90. A. Bauer, A. Villunger, V. Labi, et al., "The NF-kappaB Regulator Bcl-3 and the BH3-only Proteins Bim and Puma Control the Death of Activated T Cells," *PNAS* 103, no. 29 (2006): 10979–10984, [10.1073/pnas.0603625103](https://doi.org/10.1073/pnas.0603625103).
91. A. Köhler, A. L. Geiselhöringer, D. Kolland, et al., "The atypical IxB family Member Bcl3 Determines Differentiation and Fate of Intestinal RORyt+ Regulatory T-cell Subsets," *Mucosal Immunology* 17, no. 4 (2024): 673–691, [10.1016/j.mucimm.2024.04.002](https://doi.org/10.1016/j.mucimm.2024.04.002).
92. S. Reißig, Y. Tang, A. Nikolaev, et al., "Elevated Levels of Bcl-3 Inhibits Treg Development and Function Resulting in Spontaneous Colitis," *Nature Communications* 8 (2017): 15069, [10.1038/ncomms15069](https://doi.org/10.1038/ncomms15069).
93. R. A. Corn, C. Hunter, H. C. Liou, U. Siebenlist, and M. R. Boothby, "Opposing Roles for RelB and Bcl-3 in Regulation of T-box Expressed in T Cells, GATA-3, and Th Effector Differentiation," *Journal of Immunology* 175, no. 4 (2005): 2102–2110, [10.4049/jimmunol.175.4.2102](https://doi.org/10.4049/jimmunol.175.4.2102).
94. W. Tang, H. Wang, E. Claudio, et al., "The Oncoprotein and Transcriptional Regulator Bcl-3 Governs Plasticity and Pathogenicity of Autoimmune T Cells," *Immunity* 41, no. 4 (2014): 555–566, [10.1016/j.immuni.2014.09.017](https://doi.org/10.1016/j.immuni.2014.09.017).
95. I. A. Mufazalov, J. Kuschmann, D. Andruszewski, et al., "Balanced Bcl-3 Expression in Murine CD4(+) T Cells Is Required for Generation of Encephalitogenic Th17 Cells," *European Journal of Immunology* 47, no. 8 (2017): 1335–1341, [10.1002/eji.201746933](https://doi.org/10.1002/eji.201746933).
96. H. Liu, L. Zeng, Y. Yang, et al., "Bcl-3 Regulates the Function of Th17 Cells Through raptor Mediated Glycolysis Metabolism," *Frontiers in Immunology* 13 (2022), [10.3389/fimmu.2022.929785](https://doi.org/10.3389/fimmu.2022.929785).
97. W. Tang, S. Saret, R. Tian, et al., "Bcl-3 Suppresses Differentiation of RORyt(+) Regulatory T Cells," *Immunology and Cell Biology* 99, no. 6 (2021): 586–595, [10.1111/imcb.12441](https://doi.org/10.1111/imcb.12441).
98. H. Jaiswal, T. Ciucci, H. Wang, et al., "The NF-kappaB Regulator Bcl-3 Restricts Terminal Differentiation and Promotes Memory Cell Formation of CD8+ T Cells During Viral Infection," *Plos Pathogens* 17, no. 1 (2021): e1009249, [10.1371/journal.ppat.1009249](https://doi.org/10.1371/journal.ppat.1009249).
99. K. Hijioka, S. Matsuo, A. Eto-Kimura, K. Takeshige, and T. Muta, "Induction of the Nuclear IkbetaB Protein IkbetaB-zeta Upon Stimulation of B Cell Antigen Receptor," *Biochemical and Biophysical Research Communications* 356, no. 2 (2007): 476–480, [10.1016/j.bbrc.2007.03.002](https://doi.org/10.1016/j.bbrc.2007.03.002).
100. M. Adori, S. Khoenkhoen, J. Zhang, and X. C. Dopico, "Karlsson Hedestam GB. Enhanced B Cell Receptor Signaling Partially Compensates for Impaired Toll-Like Receptor 4 Responses in LPS-Stimulated IxBNS-Deficient B Cells," *Cells* 12, no. 9 (2023), [10.3390/cells12091229](https://doi.org/10.3390/cells12091229).
101. C. N. Arnold, E. Pirie, P. Dosenovic, et al., "A Forward Genetic Screen Reveals Roles for Nfkbid, Zeb1, and Ruvbl2 in Humoral Immunity," *PNAS* 109, no. 31 (2012): 12286–12293, [10.1073/pnas.1209134109](https://doi.org/10.1073/pnas.1209134109).
102. G. K. Pedersen, M. Adori, S. Khoenkhoen, P. Dosenovic, B. Beutler, and G. B. Karlsson Hedestam, "B-1a Transitional Cells Are Phenotypically Distinct and Are Lacking in Mice Deficient in IxBNS," *PNAS* 111, no. 39 (2014): E4119–E4126, [10.1073/pnas.1415866111](https://doi.org/10.1073/pnas.1415866111).
103. S. Khoenkhoen, M. Adori, D. Solís-Sayago, et al., "IxBNS Expression in B Cells Is Dispensable for IgG Responses to T Cell-dependent Antigens," *Frontiers in immunology* 13 (2022): 1000755, [10.3389/fimmu.2022.1000755](https://doi.org/10.3389/fimmu.2022.1000755).
104. M. Adori, G. K. Pedersen, C. Adori, et al., "Altered Marginal Zone B Cell Selection in the Absence of IxBNS," *Journal of Immunology* 200, no. 2 (2018): 775–787, [10.4049/jimmunol.1700791](https://doi.org/10.4049/jimmunol.1700791).
105. G. K. Pedersen, M. Adori, J. M. Stark, et al., "Heterozygous Mutation in IxBNS Leads to Reduced Levels of Natural IgM Antibodies and Impaired Responses to T-Independent Type 2 Antigens," *Frontiers in immunology* 7 (2016): 65, [10.3389/fimmu.2016.00065](https://doi.org/10.3389/fimmu.2016.00065).
106. S. Khoenkhoen, E. Erikson, M. Adori, et al., "TAC1 Expression and Plasma Cell Differentiation Are Impaired in the Absence of Functional IxBNS," *Immunology and Cell Biology* 97, no. 5 (2019): 485–497, [10.1111/imcb.12228](https://doi.org/10.1111/imcb.12228).
107. E. Erikson, M. Adori, S. Khoenkhoen, et al., "Impaired Plasma Cell Differentiation Associates With Increased Oxidative Metabolism in IxBNS-deficient B Cells," *Cellular Immunology* 375 (2022): 104516, [10.1016/j.cellimm.2022.104516](https://doi.org/10.1016/j.cellimm.2022.104516).
108. M. Miura, N. Hasegawa, M. Noguchi, K. Sugimoto, and M. Touma, "The atypical IxB Protein IxB(NS) Is Important for Toll-Like Receptor-

- induced Interleukin-10 Production in B Cells,” *Immunology* 147, no. 4 (2016): 453–463, [10.1111/imm.12578](https://doi.org/10.1111/imm.12578).
109. G. Franzoso, L. Carlson, T. Scharton-Kersten, et al., “Critical Roles for the Bcl-3 Oncoprotein in T Cell-Mediated Immunity, Splenic Microarchitecture, and Germinal Center Reactions,” *Immunity* 6, no. 4 (1997): 479–490, [10.1016/S1074-7613\(00\)80291-5](https://doi.org/10.1016/S1074-7613(00)80291-5).
110. S. T. Ong, M. L. Hackbarth, L. C. Degenstein, D. A. Baunoch, J. Anastasi, and T. W. McKeithan, “Lymphadenopathy, Splenomegaly, and Altered Immunoglobulin Production in BCL3 Transgenic Mice,” *Oncogene* 16, no. 18 (1998): 2333–2343, [10.1038/sj.onc.1201771](https://doi.org/10.1038/sj.onc.1201771).
111. N. Hövelmeyer, M. A. Wörns, S. Reissig, et al., “Overexpression of Bcl-3 Inhibits the Development of Marginal Zone B Cells,” *European Journal of Immunology* 44, no. 2 (2014): 545–552, [10.1002/eji.201343655](https://doi.org/10.1002/eji.201343655).
112. X. Zhang, A. Paun, E. Claudio, H. Wang, and U. Siebenlist, “The Tumor Promoter and NF- κ B Modulator Bcl-3 Regulates Splenic B Cell Development,” *Journal of Immunology* 191, no. 12 (2013): 5984–5992, [10.4049/jimmunol.1300611](https://doi.org/10.4049/jimmunol.1300611).
113. M. Ueta, J. Hamuro, E. Ueda, et al., “Stat6-independent Tissue Inflammation Occurs Selectively on the Ocular Surface and Perioral Skin of IkappaBzeta-/- mice,” *Investigative Ophthalmology & Visual Science* 49, no. 8 (2008): 3387–3394, [10.1167/iov.08-1691](https://doi.org/10.1167/iov.08-1691).
114. J. Lee, J. Alam, E. Choi, Y. K. Ko, A. Lee, and Y. Choi, “Association of a Dysbiotic Oral Microbiota With the Development of Focal Lymphocytic Sialadenitis in I κ B- ζ -deficient Mice,” *Npj Biofilms and Microbiomes* 6, no. 1 (2020): 49, [10.1038/s41522-020-00158-4](https://doi.org/10.1038/s41522-020-00158-4).
115. M. Schuster, C. Plaza-Sirvent, A. M. Matthies, et al., “c-REL and I κ B(NS) Govern Common and Independent Steps of Regulatory T Cell Development From Novel CD122-Expressing Pre-Precursors,” *Journal of Immunology* 199, no. 3 (2017): 920–930, [10.4049/jimmunol.1600877](https://doi.org/10.4049/jimmunol.1600877).
116. M. Presa, J. J. Racine, J. R. Dwyer, et al., “A Hypermorphic Nfkbid Allele Contributes to Impaired Thymic Deletion of Autoreactive Diabetogenic CD8(+) T Cells in NOD Mice,” *Journal of Immunology* 201, no. 7 (2018): 1907–1917, [10.4049/jimmunol.1800465](https://doi.org/10.4049/jimmunol.1800465).
117. X. Zhang, H. Wang, E. Claudio, K. Brown, and U. Siebenlist, “A Role for the IkappaB Family Member Bcl-3 in the Control of central Immunologic Tolerance,” *Immunity* 27, no. 3 (2007): 438–452, [10.1016/j.immuni.2007.07.017](https://doi.org/10.1016/j.immuni.2007.07.017).
118. Q. Ruan, S. J. Zheng, S. Palmer, R. J. Carmody, and Y. H. Chen, “Roles of Bcl-3 in the Pathogenesis of Murine Type 1 Diabetes,” *Diabetes* 59, no. 10 (2010): 2549–2557, [10.2337/db10-0480](https://doi.org/10.2337/db10-0480).
119. W. Tang, H. Wang, R. Tian, et al., “Bcl-3 Inhibits Lupus-Like Phenotypes in BL6/Lpr Mice,” *European Journal of Immunology* 51, no. 1 (2021): 197–205, [10.1002/eji.202048584](https://doi.org/10.1002/eji.202048584).
120. R. B. Hunter and S. C. Kandarian, “Disruption of either the Nfkb1 or the Bcl3 Gene Inhibits Skeletal Muscle Atrophy,” *The Journal of Clinical Investigation* 114, no. 10 (2004): 1504–1511, [10.1172/JCI21696](https://doi.org/10.1172/JCI21696).
121. L. Michaelis, M. Treß, H. C. Löw, et al., “Gut Commensal-Induced I κ B ζ Expression in Dendritic Cells Influences the Th17 Response,” *Frontiers in Immunology* 11 (2020): 612336, [10.3389/fimmu.2020.612336](https://doi.org/10.3389/fimmu.2020.612336).
122. N. Kakiuchi, K. Yoshida, M. Uchino, et al., “Frequent Mutations That Converge on the NFKBIZ Pathway in Ulcerative Colitis,” *Nature* 577, no. 7789 (2020): 260–265, [10.1038/s41586-019-1856-1](https://doi.org/10.1038/s41586-019-1856-1).
123. K. Nanki, M. Fujii, M. Shimokawa, et al., “Somatic Inflammatory Gene Mutations in Human Ulcerative Colitis Epithelium,” *Nature* 577, no. 7789 (2020): 254–259, [10.1038/s41586-019-1844-5](https://doi.org/10.1038/s41586-019-1844-5).
124. S. Yamazaki, N. Inohara, M. Ohmuraya, et al., “IkappaBzeta Controls IL-17-triggered Gene Expression Program in Intestinal Epithelial Cells That Restricts Colonization of SFB and Prevents Th17-Associated Pathologies,” *Mucosal Immunol* 15, no. 6 (2022): 1321–1337, [10.1038/s41385-022-00554-3](https://doi.org/10.1038/s41385-022-00554-3).
125. C. O’Carroll, G. Moloney, G. Hurley, et al., “Bcl-3 Deficiency Protects Against Dextran-Sodium Sulphate-Induced Colitis in the Mouse,” *Clinical and Experimental Immunology* 173, no. 2 (2013): 332–342, [10.1111/cei.12119](https://doi.org/10.1111/cei.12119).
126. A. Müller, A. Hennig, S. Lorscheid, et al., “I κ B ζ Is a Key Transcriptional Regulator of IL-36-driven Psoriasis-Related Gene Expression in Keratinocytes,” *PNAS* 115, no. 40 (2018): 10088–10093, [10.1073/pnas.1801377115](https://doi.org/10.1073/pnas.1801377115).
127. R. Muromoto, A. Sato, Y. Komori, et al., “Regulation of NFKBIZ Gene Promoter Activity by STAT3, C/EBP β , and STAT1,” *Biochemical and Biophysical Research Communications* 613 (2022): 61–66, [10.1016/j.bbrc.2022.04.140](https://doi.org/10.1016/j.bbrc.2022.04.140).
128. Y. Ohgakiuchi, Y. Saino, R. Muromoto, et al., “Dimethyl Fumarate Dampens IL-17-ACT1-TBK1 Axis-Mediated Phosphorylation of Regnase-1 and Suppresses IL-17-Induced I κ B- ζ Expression,” *Biochemical and Biophysical Research Communications* 521, no. 4 (2020): 957–963, [10.1016/j.bbrc.2019.11.036](https://doi.org/10.1016/j.bbrc.2019.11.036).
129. A. Alpsy, X. S. Wu, S. Pal, et al., “I κ B ζ Is a Dual-Use Coactivator of NF- κ B and POU Transcription Factors,” *Molecular Cell* 84, no. 6 (2024): 1149–1157, [10.1016/j.molcel.2024.01.007](https://doi.org/10.1016/j.molcel.2024.01.007).
130. Z. Wu, X. Zhang, J. Yang, et al., “Nuclear Protein IkappaB-zeta Inhibits the Activity of STAT3,” *Biochemical and Biophysical Research Communications* 387, no. 2 (2009): 348–352, [10.1016/j.bbrc.2009.07.023](https://doi.org/10.1016/j.bbrc.2009.07.023).
131. G. Totzke, F. Essmann, S. Pohlmann, C. Lindenblatt, R. U. Janicke, and K. Schulze-Osthoff, “A Novel Member of the IkappaB Family, Human IkappaB-zeta, Inhibits Transactivation of p65 and Its DNA Binding,” *Journal of Biological Chemistry* 281, no. 18 (2006): 12645–12654, [10.1074/jbc.M511956200](https://doi.org/10.1074/jbc.M511956200).
132. F. Michel, M. Soler-Lopez, C. Petosa, P. Cramer, U. Siebenlist, and C. W. Muller, “Crystal Structure of the Ankyrin Repeat Domain of Bcl-3: A Unique Member of the IkappaB Protein family,” *Embo Journal* 20, no. 22 (2001): 6180–6190, [10.1093/emboj/20.22.6180](https://doi.org/10.1093/emboj/20.22.6180).
133. T. Walker, A. Adamson, and D. A. Jackson, “BCL-3 Attenuation of TNFA Expression Involves an Incoherent Feed-Forward Loop Regulated by Chromatin Structure,” *PLoS ONE* 8, no. 10 (2013): e77015, [10.1371/journal.pone.0077015](https://doi.org/10.1371/journal.pone.0077015).
134. B. Gaire, S. Padmanabhan, Y. Zou, M. M. Uddin, S. U. Reddy, and I. Vancurova, “IFN γ Induces Bcl3 Expression by JAK1/STAT1/p65 Signaling, Resulting in Increased IL-8 Expression in Ovarian Cancer Cells,” *FEBS Open Bio* 13, no. 8 (2023): 1495–1506, [10.1002/2211-5463.13624](https://doi.org/10.1002/2211-5463.13624).
135. K. Brocke-Heidrich, B. Ge, H. Cvijic, et al., “BCL3 is Induced by IL-6 via Stat3 Binding to Intronic Enhancer HS4 and Represses Its Own Transcription,” *Oncogene* 25, no. 55 (2006): 7297–7304, [10.1038/sj.onc.1209711](https://doi.org/10.1038/sj.onc.1209711).
136. D. L. Bundy and T. W. McKeithan, “Diverse Effects of BCL3 Phosphorylation on Its Modulation of NF-kappaB p52 Homodimer Binding to DNA,” *Journal of Biological Chemistry* 272, no. 52 (1997): 33132–33139, [10.1074/jbc.272.52.33132](https://doi.org/10.1074/jbc.272.52.33132).
137. P. E. Collins, P. A. Kiely, and R. J. Carmody, “Inhibition of Transcription by B Cell Leukemia 3 (Bcl-3) Protein Requires Interaction With Nuclear Factor κ B (NF- κ B) p50,” *Journal of Biological Chemistry* 289, no. 10 (2014): 7059–7067, [10.1074/jbc.M114.551986](https://doi.org/10.1074/jbc.M114.551986).
138. G. Franzoso, V. Bours, V. Azarenko, et al., “The Oncoprotein Bcl-3 Can Facilitate NF-kappa B-Mediated Transactivation by Removing Inhibiting p50 Homodimers From Select Kappa B Sites,” *Embo Journal* 12, no. 10 (1993): 3893–3901, [10.1002/j.1460-2075.1993.tb06067.x](https://doi.org/10.1002/j.1460-2075.1993.tb06067.x).
139. S. Tartey, K. Matsushita, A. Vandenbon, et al., “Akirin2 is Critical for Inducing Inflammatory Genes by Bridging I κ B- ζ and the SWI/SNF Complex,” *Embo Journal* 33, no. 20 (2014): 2332–2348, [10.15252/emboj.201488447](https://doi.org/10.15252/emboj.201488447).
140. V. Y. Wang, W. Huang, M. Asagiri, et al., “The Transcriptional Specificity of NF- κ B Dimers Is Coded Within the κ B DNA Response Elements,” *Cell reports* 2, no. 4 (2012): 824–839, [10.1016/j.celrep.2012.08.042](https://doi.org/10.1016/j.celrep.2012.08.042).